FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 350:84-85 January 1, 2004 Number 1 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Klugman, K. P. PubMed Citation

To the Editor: In their trial of a 9-valent pneumococcal conjugate vaccine in children with human immunodeficiency virus infection and those without infection, Klugman and colleagues (Oct. 2 issue)¹ found an increased risk of asthma among vaccinees. We assessed this risk in a randomized, controlled trial of the 7-valent pneumococcal conjugate vaccine in northern California.²

From 1995 to 1998, a total of 37,868 children at Kaiser Permanente received pneumococcal conjugate vaccine or control meningococcal C conjugate vaccine. The risk of a first hospitalization or emergency department visit for asthma (International Classification of Diseases, code 493.xx) was assessed with the . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.